Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections

Zanetti, G; Harbarth, Stéphan Juergen; Trampuz, A; Ganeo, M; Mosimann, F; Chautemps, R; Morel, Philippe; Lew, Daniel Pablo; Zimmerli, W; Lange, J; Glauser, M

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections
Authors		Zanetti, G Harbarth, Stéphan Juergen Trampuz, A Ganeo, M Mosimann, F Chautemps, R Morel, Philippe Lew, Daniel Pablo Zimmerli, W Lange, J Glauser, M show all authors [1 - 11]
Published in		International Journal of Antimicrobial Agents. 1999, vol. 11, no. 2, p. 107-13
Abstract		This multicentre, open-label, randomised trial compared meropenem (0.5 g/8 h) and imipenem/cilastatin (at the commonly used dosage of 0.5 g/6 h) in monotherapy in patients with moderately severe intra-abdominal infections (IAIs). In total, 161 patients were randomised (82 meropenem, 79 imipenem/cilastatin). The mean APACHE II scores in the two groups were 5.8 and 6.4, respectively. At the end of therapy, 65/71 (91.6%) evaluable meropenem recipients were clinically cured or improved, compared to 60/64 (93.8%) imipenem/cilastatin recipients. This difference and that in an intention-to-treat analysis (82.1 vs 86.1%, respectively), were not statistically significant. Both drugs were generally well tolerated. Thus, meropenem 0.5 g/8 h is as clinically effective and well tolerated as imipenem/cilastatin 0.5 g/6 h in moderately severe IAIs.
Keywords		APACHE — Adult — Cilastatin/administration & dosage/therapeutic use — Drug Therapy, Combination — Female — Humans — Imipenem/administration & dosage/therapeutic use — Male — Middle Aged — Peritonitis/drug therapy — Thienamycins/administration & dosage/therapeutic use
Identifiers		DOI: 10.1016/s0924-8579(98)00104-6 PMID: 10221413
Full text		Article (Published version) (96 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités Faculté de médecine / Section de médecine clinique / Département de chirurgie
Research group		Chirurgie viscérale (104)
Citation (ISO format)		ZANETTI, G et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. In: International Journal of Antimicrobial Agents, 1999, vol. 11, n° 2, p. 107-13. https://archive-ouverte.unige.ch/unige:73145